RESEARCH: HALOGENASES
FOLDING PROJECT #19215 PROFILE

Many new medicines use halogens (like fluorine) as key ingredients. Adding these halogens to make drugs is tricky, though. Scientists are studying special enzymes called halogenases that do this job naturally and very precisely. This project uses computer models to predict how well different enzymes will add halogens to various drug building blocks.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

halogens

Elements fluorine (F), chlorine (Cl), bromine (Br), and iodine (I)

Halogens are a group of highly reactive elements used in pharmaceuticals. They can be incorporated into drug molecules to alter their properties and improve their effectiveness. However, controlling the addition of halogens during chemical synthesis can be challenging.

---

pharmaceutically active ligand

A molecule that binds to a specific biological target and produces a pharmacological effect.

Pharmaceutically active ligands are the core components of drugs. They interact with specific targets in the body, such as proteins or receptors, to trigger a desired biological response.

---

medicinal chemists

Scientists who design and synthesize new drugs.

Medicinal chemists are experts in organic chemistry and drug development. They use their knowledge to create novel molecules with therapeutic potential.

---

halogenation

The introduction of a halogen atom into an organic molecule.

Halogenation is a common chemical reaction used to modify the properties of molecules. It involves adding a halogen atom, such as fluorine or chlorine, to a carbon-containing compound.

---

regioselectivity

The preferential formation of one isomer over others.

Regioselectivity refers to the control of where a chemical reaction occurs on a molecule. In organic synthesis, it's crucial to achieve regioselectivity to obtain the desired product.

---

byproducts

Unwanted substances produced during a chemical reaction.

Byproducts are often undesirable as they can be toxic or interfere with the desired outcome of a chemical process.

---

halogenases

Enzymes that catalyze the regioselective halogenation of molecules.

Halogenases are a class of enzymes found in nature. They have the unique ability to selectively add halogens to organic molecules, which has potential applications in drug development.

---

Relative Binding Free Energy calculations (RBFE)

Method for predicting the binding affinity of molecules to a target.

RBFE calculations are used in drug discovery to assess how well a potential drug molecule binds to its intended target. This information helps researchers identify promising candidates for further development.

---

scaffolds

Basic molecular frameworks that can be modified to create new drug candidates.

Scaffolds are fundamental building blocks in drug design. They provide a starting point for creating diverse molecules with specific pharmacological properties.